[Interferon alpha in the treatment of malignant hematologic diseases].
The majority of malignant haematological diseases is incurable by contemporary procedures and therefore new approaches are sought, based on recent findings on haematopoiesis and its regulation. One of the new approaches is the use of so-called biological response modifiers between the later interferons. Recently relatively abundant experience was assembled with therapy using alpha interferon. The author presents an account of hitherto achieved therapeutic results obtained with alpha interferon in neoplasias of myelopoiesis and lymphopoiesis.
Steruská
M
M
D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008232:Lymphoproliferative Disorders / Q000628:therapy*
D007370:Interferon Type I
Interferón alfa v liecbe zhubných hematologických ochorení.